跳至主要内容
临床试验/NCT02699658
NCT02699658已完成2 期

Population Pharmacokinetics and Pharmacodynamics Modeling to Optimize Dosage Regimen of Levofloxacin

Prince of Songkla University1 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2013年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
45
试验地点
1
主要终点
concentration of levofloxacin in plasma

研究概览

简要总结

Levofloxacin, a fluoroquinolone antibiotic, is the optical S-(-) isomer of ofloxacin with a broad spectrum of activity. In common with other fluoroquinolones, the main pharmacokinetic/pharmacodynamic (PK/PD) index that correlates with its therapeutic efficacy is the area under the plasma time-concentration curve/the minimum inhibitory concentration ratios.

The aims of the study were to:

  1. reveal the population pharmacokinetics, and
  2. assess the efficacy of various dosage regimens in achieving the probability of target attainment (PTA) and the cumulative fraction of response (CFR) of levofloxacin when oral levofloxacin was prescribed as the switching therapy after intravenous levofloxacin treatment.

The study was conducted in 45 healthy volunteers. Each subject received one 500 mg tablet of levofloxacin, after which PK studies were carried out, using a Monte Carlo simulation to determine the PTA. By referral to the EUCAST MIC distributions database, the dosage regimens were predicted to achieve CFR greater than or equal to 90%.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
盲法
None

入排标准

年龄范围
20 Years 至 45 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

levofloxacin in healthy

Experimental

干预措施: Levofloxacin (Drug)

结局指标

主要结局

concentration of levofloxacin in plasma

时间窗: up to 2 week after blood collection

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Sutep Jaruratanasirikul

Prince of Songkla University

Prince of Songkla University

研究点 (1)

Loading locations...

相似试验

Population Pharmacokinetics and Pharmacodynamics... | 临床试验